After nearly 6 years overseeing public health initiatives, Margaret Hamburg, MD, commissioner of the FDA will be stepping down, according to various sources.
After nearly 6 years overseeing public health initiatives, Margaret Hamburg, MD, commissioner of the FDA will be stepping down, according to various sources.
Reuters is reporting that Dr Hamburg’s resignation will be announced on Friday, although as of right now a new commissioner has not been named. Until then, Stephen Ostroff, MD, the FDA’s chief scientist, will fill the position.
The Wall Street Journal conjectured that Robert Califf, MD, from Duke University, who was recently appointed as FDA deputy commissioner for medical products and tobacco, will likely become the next FDA commissioner.
On January 27, when Dr Califf’s appointment was announced, experts began speculating that he was part of an FDA succession plan because he would quickly be confirmed.
“Dr Califf’s deep knowledge and experience in the areas of medicine and clinical research will enable the agency to capitalize on, and improve upon, the significant advances we’ve made in medical product development and regulation over the last few years,” Dr Hamburg had said in a statement upon Dr Califf’s appointment.
Dr Hamburg is one of the longest-serving FDA commissioners. During her time as commissioner, she relaxed age restrictions on the Plan B contraceptive and faced the challenge of hundreds of deaths caused by compounded drugs mixed at a local pharmacy.
Under her leadership, the FDA also introduced measures to speed the development and review of new drugs and the agency gained regulatory authority over tobacco products.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Exploring Pharmaceutical Innovations, Trust, and Access With CVS Health's CMO
July 11th 2024On this episode of Managed Care Cast, we're talking with the chief medical officer of CVS Health about recent pharmaceutical innovations, patient-provider relationships, and strategies to reduce drug costs.
Listen
FDA Approves Danziten for Chronic Myeloid Leukemia Without Mealtime Restrictions
November 14th 2024The FDA has granted approval to Azurity Pharmaceuticals' nilotinib tablets (Danziten), a novel version of the tyrosine kinase inhibitor for chronic myeloid leukemia that can be taken without mealtime restrictions.
Read More